Association of Prophylactic Treatment With Treatment Burden and Psychosocial Variables in Patients With Hemophilia

Inclusion Criteria: * Patients over 18 years of age. * Patients with a medical diagnosis of hemophilia A or B. * Patients who, regardless of disease phenotype (mild, moderate or severe), are receiving prophylactic treatment with recombinant or plasma clotting factor concentrates, either short half-life or extended half-life. * Patients must have maintained the same treatment regimen (SHL or EHL) continuously for at least six months prior to participation. Exclusion Criteria: * Patients who have developed inhibitors or antibodies to FVIII or FIX concentrates. * People with a concomitant diagnosis of other serious or disabling chronic diseases (neurological, oncological, severe psychiatric or rheumatological) that may interfere with the perceived burden of treatment, sleep quality, functionality or perception of self-efficacy. * Patients with cognitive, linguistic or sensory impairments that prevent them from correctly understanding and completing the questionnaires. * Patients who are participating in clinical trials or intensive monitoring programmes that may alter their perception of the treatment and generate biases in the evaluation.